莫西沙星联合环丝氨酸治疗耐多药肺结核患者的临床效果

Clinical Efficacy of Moxifloxacin Combined with Cycloserine in the Treatment of Multi-drug Resistant Pulmonary Tuberculosis

目的分析莫西沙星联合环丝氨酸治疗耐多药肺结核患者的临床效果。方法选择于我院接受治疗的60例耐多药肺结核患者为研究对象,时间为2017年1月至2019年1月,按照治疗方法的不同分为对照组(n=30)和观察组(n=30),对照组采用莫西沙星治疗,观察组采用莫西沙星联合环丝氨酸治疗。治疗后分别对两组患者的治疗结果进行比较。结果两组患者通过治疗后均有一定程度的好转。观察组患者治疗12、15、20个月后的痰菌转阴率、治疗总有效率明显高于对照组患者,且不良反应发生率明显低于对照组患者(P<0.05)。结论应用莫西沙星联合环丝氨酸治疗耐多药肺结核患者的临床效果显著,能够降低患者发生不良反应的概率,提升治疗安全性。

Objective To study the clinical efficacy of moxifloxacin combined with cycloserine in the treatment of multi-drug resistant pulmonary tuberculosis(MDR-TB). Methods A total of 60 patients with MDR-TB treated in our hospital from January 2017 to January 2019 were divided into control group and observation group according to different treatment methods, 30 cases in each group. The control group was given moxifloxacin, and the observation group was given moxifloxacin combined with cycloserine. After treatment, the treatment results of the two groups were analyzed. Results The two groups of patients improved to some extent through treatment. The sputum negative conversion rate and total effective rate of the observation group patients after 12, 15, 20 months of treatment were significantly higher than those of the control group, and the incidence of adverse reactions was significantly lower than that of the control group patients(P<0.05). Conclusion The clinical effect of moxifloxacin combined with cycloserine in the treatment of MDRTB is remarkable, which can reduce the incidence of adverse reactions, and is safety.